Curriculum Vitae

1. Personal and contact information

Name (First FAMILY) : Hiromi SATO, Ph.D.

Current Position: Associatet Professor,

Laboratory of Clinical Pharmacology & Therapeutics,

Graduate School of Pharmaceutical Sciences, Chiba University

Office Address: 1-8-1, Inohana, Chuou-ku, Chiba-shi, Chiba 260-8675 JAPAN

Phone: +81-43-226-2879

E-mail: hiromi-s@chiba-u.jp

2.Education

2004

Faculty of Pharmaceutical Sciences, Chiba University

2006

Graduate School of Pharmaceutical Sciences, Master (Pharmacy), Chiba University

2008

Graduate School of Pharmaceutical Sciences, Ph.D. (Pharmaceutical Sciences), Chiba Univeristy

3.Academic appointments and other professional positions

2008-2018

Assistant Professor, Lab of Geriatric Pharmacology and Therapeutics (Current: Lab of Clinical Pharmacology and Pharmacometirics), Graduate School of Pharmaceutical Sciences, Chiba University

2011 April-June

Visiting Scientist (The Institutional Program for Young Researcher Overseas Visits, JSPS), Dept. of Cellular & Physiological Sciences, LSI, The University of British Columbia (Prof. Christian C. Naus), Canada

2018-

Associate Professor, Lab of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University

4. Members of Societies

- The Japanese Pharmacological Society (JPS)

- The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

- The Pharmaceutical Society of Japan

- The Japanese Society for the Study of Xenobiotics (JSSX)

- Japanese Cancer Association (JCA)

-American Association for Cancer Research (AACR)

-The Japanese Society of Toxicology (JSOT)

-The Japanese Association for Gender-Specific Medicine

- Japanese Society for Pharmaceutical Palliative Care and Sciences

5. Activities of Societies

2011-

Member of Next Generation Scientist, Division of Clinical Pharmaceutical Sciences, The Pharmaceutical Society of Japan

2013-

Member of Next Generation Scientist, Division of Pharmacology & Drug Therapeutics, The Pharmaceutical Society of Japan

2012-

Member of Scientific Council, The Japanese Pharmacological Society

2012-

Member of Scientific Council, Japanese Society for Pharmaceutical Palliative Care and Sciences

2022-

Member of Scientific Council, The Japanese Association for Gender-Specific Medicine

2022-

Member of Scientific Council, The Japanese Society of Toxicology

6. Awards

2012

Pfizer Highly Cited Paper Award (The Japanese Society of Toxicology)

Yamaura K, Oda M, Suwa E, Suzuki M, Sato H, Ueno K.

2015

The Best Presentation Award (40th Annual Meeting of Chiba Oriental Medicine Symposium)

Sato H.

2018

The Best Poster Award (1oth Annual Meeting of The Japanese Association for Gender-Specific Medicine)

Ueno K, Sato H.

2019

The Best Research Award (Japanese Research Foundation for Clinical Pharmacology)

Sato H.

2022

The Incentive Award (Division of Pharmacology & Drug Therapeutics , The Japanese Research Foundation for Clinical Pharmacology, The Pharmaceutical Society of Japan)

Sato H.

6. Other information

researchmap

https://researchmap.jp/hiromisato

7. Biography

[Original Articles] (Recent 5 years) *; corresponded author

1. Hozuki S, Yoshioka H, Asano S, Nakamura M, Koh S, Shibata Y, Tamemoto Y, **Sato H**, Hisaka A. Integrated use of in vitro and in vivo information for comprehensive prediction of drug interactions due to inhibition of multiple CYP isoenzymes. Clinical Pharmacokinetics, 2023, in press.

2. Tamemoto Y, Shibata Y, Hashimoto N, **Sato H**, Hisaka A. Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants. Drug Metabolism and Pharmacokinetics. 2023, in press.
3. Yoshitomo A, Asano S, Hozuki S, Tamemoto Y, Shibata Y, Hashimoto N, Takahashi K, Sasaki Y, Ozawa N, Kageyama M, Iijima T, Kazuki Y, **Sato H**, Hisaka A. Significance of basal membrane permeability of epithelial cells in predicting intestinal drug absorption. Drug Metabolism and Diposition. 2023;51(3):318-328.
4. Soejima K, **Sato, H**, Hisaka A. Age-related change in hepatic clearance inferred from multiple population pharmacokinetic studies: Comparison with renal clearance and their associations with organ weight and blood flow. Clinical Pharmacokinetics, 2021, 61(2):295-305.
5. Okawa T, Hara K, Goto M, Kiukuchi M, Kogane M, Hatakeyama H, Tanaka H, Shirane D, Akita H, Hisaka H, and **Sato H***. Effects on Metabolism in Astrocytes Caused by cGAMP, Which Imitates the Initial Stage of Brain Metastasis. Int. J. Mol. Sci, the Special Issue: Astrocytes: Emerging Roles in the Pathogenesis and Treatment of CNS Disorders 2.0. 22(16), 9028, 2021.
6. **Sato H***, Shimizu A, Okawa T, Uzu M, Goto M, Hisaka A. Metabolome Shift in Both Metastatic Breast Cancer Cells and Astrocytes Which May Contribute to the Tumor Microenvironment. Int. J. Mol. Sci, the Special Issue: The Molecular Basis of Therapeutic Resistance of Brain Tumor. 22(14)7430, 2021.
7. Shibata Y, Tamemoto Y, Singh S.P, Yoshitomo A, Hozuki S, **Sato H**, Hisaka A. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Drug Metabolism and Pharmacokinetics. 2021, 39, 100396.
8. Asano S, Yoshitomo A, Hozuki S, **Sato H**, Kazuki Y, Hisaka A. A new intestinal model for analysis of drug absorption and interactions considering physiological translocation of contents. Drug metabolism and disposition. 49(7):581-591, 2021.

9. Takaoka R, Soejima Y, Guro S, Yoshioka H, **Sato H**, Suzuki H, Akihiro Hisaka. Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure: MBMA of circulatory system physiology in CHF. CPT Pharmacometrics Syst Pharmacol. 10(9):1081-1091, 2021
10. Kawamatsu S, Jin R, Araki S, Yoshioka H, **Sato H**, Sato Y, Hisaka A. Scores of Health-Related Quality of Life Questionnaire Worsen Consistently in Patients of COPD: Estimating Disease Progression over 30 Years by SReFT with Individual Data Collected in SUMMIT Trial. J Clin Med. 2020;9:2676.
11. Hisaka A, Yoshioka H, Hatakeyama H, **Sato H**, Onouchi Y, Anzai N. Global comparison of changes in the number of testpositive cases and deaths by Coronavirus Infection (COVID-19) in the World. J Clin Med. 2020;9:1904.
12. Tomizawa S, Tamori M, Tanaka A, Utsumi N, **Sato H**, Hatakeyama H, Hisaka A, Kohama T, Yamagata K, Honda T, Nakamura H, Murayama T. "Inhibitory effects of ceramide kinase on Rac1 activation, lamellipodium formation, cell migration, and metastasis of A549 lung cancer cells.". Biochimica et biophysica acta Molecular and cell biology of lipids. 2020;1865:158675.
13. Uzu M, Nonaka M, Miyano K, **Sato H**, Kurebayashi N, Yanagihara K, Sakurai T, Hisaka A, Uezono Y. A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain. Journal of pharmacological sciences. 2019;140:109-12.
14. Oishi N, Iwata H, Kambe N, Kobayashi N, Fujimoto K, **Sato H**, Hisaka A, Ueno K, Yamaura K. Expression of precipitating factors of pruritus found in humans in an imiquimod-induced psoriasis mouse model. Heliyon. 2019;5:e01981.
15. **Sato H***, Uzu M, Kashiba T, Fujiwara T, Hatakeyama H, Ueno K, Hisaka A. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity. European journal of pharmacology. 2019;847:143-57.

16. Kaneko S, Sato C, Shiozawa N, Sato A, **Sato H**, Virgona N, Yano T. Suppressive effect of delta-tocotrienol on hypoxia adaptation of prostate cancer stem-like cells. Anticancer Research. 2018;38:1391-9.
17. Hatakeyama H, Fujiwara T, **Sato H**, Terui A, Hisaka A. Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. Biological and Pharmaceutical Bulletin. 2018;41:619-27.
18. Yoshioka H, **Sato H**, Hatakeyama H, Hisaka A. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood advances. 2018;2:1066-75.
19. Uzu M, **Sato H***, Shimizu A, Shibata Y, Ueno K, Hisaka A. Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells. JOURNAL OF PHARMACOLOGICAL SCIENCES. 2017;134:101-7.
20. **Sato H***, Uzu M, Kashiba T, Suzuki R, Fujiwara T, Okuzawa H, Ueno K. Sodium butyrate enhances the growth inhibitory effect of sunitinib in human renal cell carcinoma cells. ONCOLOGY LETTERS. 2017;14:937-43.
21. Ploenes T, Fischer M, Hoehne K, **Sato H**, Mueller-Quernheim J, Zissel G. "Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis". PATHOLOGY & ONCOLOGY RESEARCH. 2017;23:723-30.
22. Ando H, Hatakeyama H, **Sato H**, Hisaka A, Suzuki H. Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models. JOURNAL OF PHARMACEUTICAL SCIENCES. 2017;106:2771-9.

[Books & Reviews] *; corresponded author

1. Uzu M, Sin WC, Shimizu A, **Sato H***. Conflicting roles of connexin43 in tumor invasion and growth in the central nervous system. International Journal of Molecular Sciences. 2018;19:null.
2. **Sato H***, Ishikawa M, Sugai H, Funaki a, Kimura Y, Sumitomo M, Ueno K. Sex hormones influence expression and function of peroxisome proliferator activated receptor γ in adipocytes: pathophysiological aspects. Horm Mol Biol Clin Investig. 2014;20:51-61.
3. **Sato H***, Ueno K. Chapter 10: Connexin 43 Enhances the Cisplatin-Induced Cytotoxicity in Mesothelioma Cells, Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis. Alexander Zubritsky (Ed.), ISBN: 978-953-307-845-8, InTech, pp.153-168, 2012
4. Yano T, **Sato H**, Hagiwara H, Virgona N. Connexin genes promising therapeutic targets in cancers. Current Pharmacogenomics. 2007;5:314-8.
5. **Sato H**, Hagiwara H, Ohde Y, Senba H, Virogona N, Yano T. Regulation of eanal cell carcinoma cell proliferation, invasion, and metastasis by connexin 32 gene. J Membrane Biol. 2007;216:17-21.
6. Yano T, Fujimoto E, Hagiwara H, **Sato H**, Yamasaki H, Negishi E, Ueno K. Connexin 32 as an anti-invasive and anti-metastatic gene in renal cell carcinoma. BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2006;29:1991-4.